Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
Kathleen N. Moore(University of Oklahoma Medical Center), Bradley J. Monk(Florida Cancer Specialists & Research Institute), John K. Chan(Sutter Health), Yong Li(Sutherland Hospital), Jonathan S. Berek(Stanford Health Care), Melissa A. Geller(University of Minnesota), Masoud Azodi(Yale University), Paul DiSilvestro(Women & Infants Hospital of Rhode Island), David S. Miller(Southwestern Medical Center), Gini F. Fleming(University of Chicago Medical Center), Mihaela Cristea(City Of Hope National Medical Center), Ursula A. Matulonis(Dana-Farber Cancer Institute), Angeles Alvarez Secord(Duke University), Katarina Luptakova(Tesaro (United States)), Noelle Cloven(Texas Oncology), Daniela Matei(Northwestern University), Amit M. Oza(Ontario Institute for Cancer Research), B.J. Rimel(Cedars-Sinai Medical Center), Kaiming Sun(Tesaro (United States)), Andrea E. Wahner Hendrickson(Mayo Clinic in Arizona)
Cited by 533
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix
|Journal of Clinical Oncology|2000|2.3k
Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial
|The Lancet|2014|1.8k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k